Document Detail

Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis.
MedLine Citation:
PMID:  20374310     Owner:  NLM     Status:  MEDLINE    
AIMS: In order to investigate the histological change in effect attenuation cases of etanercept compared with methotrexate (MTX), we performed immunohistochemical examination by seven different molecules. METHODS: We histologically assessed synovial tissue from five MTX-treated rheumatoid arthritis (RA) patients as control and six etanercept and MTX-treated RA patients after synovectomy by arthroscopy. The synovium of both groups were assessed by hematoxylin and eosin (HE) and we also analysed the expression of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), B-cell precursors and mature B-cell transmembrane protein, CD20, macrophage marker, CD68, bromodeoxyuridine (BrdU) and vascular endothelial growth factor (VEGF) by immunohistochemistry. RESULTS: HE staining showed vascular and cell proliferations of the synovium of the RA patients who received etanercept compared with the control MTX group. TNF-alpha and IL-6 were expressed in both groups.MMP-3 and CD68 expressed less significantly in the etanercept group compared with the control (P < 0.05). CD20 strongly expressed in the etanercept group significantly (P < 0.05). BrdU expressed in the synovium in the etanercept group significantly (P < 0.05). VEGF was not found overall in both group. CONCLUSION: Based on the histological change of synovium, treatment by etanercept may be involved in vascular and cell proliferations with inhibition of the expression of CD68 and MMP-3 in synovium of RA patients. These findings indicate immunohistochemical change of synovium with etanercept is one of the mechanism of efficacy of etanercept.
Yutaka Suzuki; Kazuhiko Inoue; Junji Chiba; Yasuo Inoue; Katsuaki Kanbe
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of rheumatic diseases     Volume:  12     ISSN:  1756-185X     ISO Abbreviation:  Int J Rheum Dis     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2010-04-08     Completed Date:  2010-06-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101474930     Medline TA:  Int J Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  7-13     Citation Subset:  IM    
Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa, Tokyo 116-8567, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / metabolism
Antigens, Differentiation, Myelomonocytic / metabolism
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  metabolism,  pathology
Biological Markers / metabolism
Fluorescent Antibody Technique, Indirect
Immunoglobulin G / therapeutic use*
Interleukin-6 / metabolism
Matrix Metalloproteinase 3 / metabolism
Methotrexate / therapeutic use*
Middle Aged
Receptors, Tumor Necrosis Factor / therapeutic use*
Synovial Membrane / drug effects*,  metabolism,  pathology
Tumor Necrosis Factor-alpha / metabolism
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, Differentiation, Myelomonocytic; 0/Antirheumatic Agents; 0/Biological Markers; 0/CD68 antigen, human; 0/IL6 protein, human; 0/Immunoglobulin G; 0/Interleukin-6; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 59-05-2/Methotrexate; EC Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of androgen receptor CAG repeat polymorphism with VO?max response to hypoxic training in...
Next Document:  Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh Hospi...